Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
August 5, 2021
Earnings Call Speaker Segments
Jennifer Ruddock
executiveCrystal, thanks, and good afternoon to all of you. We appreciate you being with us today. Joining us on this call are our President and CEO, Howard Robin; our COO and CFO, Gil Labrucherie; Dr. Jonathan Zalevsky, who serves as our Chief of Research and Development; and Dr. Dimitry Nuyten, who has just become our Chief Medical Officer. During this call, we anticipate delivering forward-looking statements about our business, among them clinical trial enrollment and clinical trial results, the timing of and plans for upcoming clinical trials, the timing of and plans for upcoming clinical data presentations, the therapeutic potential of our drug candidates; outcomes and plans concerning health authority regulatory actions and decisions; financial guidance, plus certain other statements about the future of our business. Since forward-looking statements concern the future, they carry inherent uncertainties and risks that are hard to predict and many of which lie outside our control. Our actual results could differ materially from those statements. Key risks and uncertainties appear in the Form 10-Q filed on May 7, 2021, which you can find at sec.gov. We assume no obligation to update any of these forward-looking statements, whether because of new information, future developments or otherwise. A webcast of this call will be accessible on the IR page of Nektar's website at nektar.com. Before I hand things over to Howard, I want to remind you once more that, since we're dialing in from different locations, I'll be moderating the Q&A session for our team, which lets us avoid technical issues during the session. We appreciate your patience; having said that, I'd like to pass the call to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveThanks, Jennifer, and I appreciate all of you being with us on today's call. From the start of 2021, we have kept moving our extensive portfolio forward in immuno-oncology and immunology, which positions us for a consistent flow of important data results beginning in this year's second half and extending into the first half of 2022. These datasets should give us the foundation for a sequence of BLA submissions and commercial introductions of BEMPEG across several frontline solid tumor indications. Every investigational candidate we have in development—BEMPEG, NKTR-255 and NKTR-358—brings its own unique worth and wide-ranging development possibilities; taken together, our clinical pipeline stands as one of the most varied and foremost cytokine portfolios currently in development, reflecting our trailblazing efforts in targeting cytokine biology and engineering cytokine conjugates. Beyond our clinical portfolio, we keep putting resources into immune science and cytokine biology to fuel the coming generation of IND candidates. Operationally speaking, we came into the third quarter of 2021 with a remarkably robust balance sheet, holding more than $1 billion in cash and carrying no debt. Through our strategic collaborations, we receive considerable funding backing for specific trials. Regarding our partnership with BMS, that arrangement includes a potential $1.4 billion in filing and approval milestones for BEMPEG across the US, Europe and Japan. And keep in mind, those milestones apply to any approval of BEMPEG, regardless of whether that approval involves combination with nivo. So I'll start today with BEMPEG, our furthest-along clinical program, an IL-2 pathway agonist under development alongside checkpoint inhibitors nivo and pembro in several sizable frontline and adjuvant tumor settings. Through our alliance with BMS, five registrational studies of BEMPEG plus nivo are underway and progressing well. We hold a distinctive position with three registrational trials for BEMPEG that should produce results during the first half of 2022. Those consist of the Phase 3 trial in metastatic melanoma, the Phase 3 trial in renal cell carcinoma and the Phase 2 accelerated approval trial in PD-L1 low cisplatin-ineligible bladder cancer; we also have, together with our partner BMS, two further large Phase 3 trials, one in adjuvant melanoma and one in muscle-invasive bladder cancer. Both of those indications present a chance to broaden the patient populations in melanoma and bladder cancer and might allow patients to benefit from BEMPEG treatment earlier in the course of those diseases. Furthermore, BMS is running a Phase 2 trial in renal cell carcinoma testing BEMPEG plus nivo with a TKI, laying groundwork for later development of a regimen that includes a TKI, following on their recent successful approval of nivo plus cabo. When it comes to our approach for BEMPEG plus pembro, our top priority is to concentrate on the biggest settings where pembro serves as the gold standard of care, non-small cell lung cancer and head and neck cancer. In that situation, we can pair BEMPEG with pembro and conduct a head-to-head trial versus pembro given alone, structured to support registration. Later in the year, we expect to share results from our Phase 2 PROPEL trial in non-small cell lung cancer, and those findings will shape how we pursue registration for the doublet, whether combined with chemotherapy or not, in that disease. Pembro has extended overall survival for non-small cell lung cancer patients, yet the advantage it delivers tends to plateau at roughly 2 years. That leaves room, in our view, to boost the benefit across several regimens and simultaneously provide a chemotherapy-free option for this tumor type. We have likewise moved forward well in getting ready to begin our Phase 2/3 trial of pembro plus BEMPEG in head and neck cancer. Things are moving faster than planned, and we now anticipate that enrollment will begin in the coming months. This doublet could raise and deepen responses relative to pembro by itself in this cancer, which is known to be immune sensitive, and that prospect excites us. In first-line treatment of head and neck cancer, pembro holds roughly 75% of market share. Given a number of recent Phase 3 disappointments in this indication, the promise of this doublet — the top checkpoint inhibitor paired with our distinctive IL-2 mechanism — leaves us especially optimistic. Another compelling prospect at an earlier stage of development is NKTR-255, our second immuno-oncology candidate, an IL-15 agonist that has shown it can expand natural killer cells, CD8 T cells and memory T cells. Because of these distinctive qualities, NKTR-255 might cover an even broader range of tumor types than BEMPEG, in both liquid and solid tumors. A strong development plan is already in place, starting with pairing NKTR-255 with antibodies that rely on antibody-dependent cellular cytotoxicity, or ADCC, to destroy cancer cells, since those antibodies need functioning NK cells to work. We recognize that sustained expansion of natural killer cells via an IL-15 mechanism can substantially boost the activity of such ADCC agents; we currently have 2 studies underway — 1 in solid tumors testing cetuximab with a focus on colorectal cancer and head and neck cancer, and 1 in liquid tumors testing rituximab with a focus on non-Hodgkin lymphoma along with daratumumab with a focus on multiple myeloma. Later in the year, at medical meetings, we look forward to giving data updates from these trials. NKTR-358 is the portfolio's third cytokine, and it is being developed for autoimmune disease alongside Eli Lilly to tackle a wide spectrum of autoimmune and inflammatory conditions. NKTR-358 acts on the IL-2 receptor complex so as to drive proliferation of potent inhibitory immune cells called regulatory T cells. Through activating those cells, NKTR-358 may restore the immune system to balance. Looking at what's been happening lately in the Treg mobilizing space — Merck buying Pandion Therapeutics stands out as one example — Lilly clearly holds the top position here, given how broadly they're developing things and how far along the NKTR-358 program has gotten in the clinic. On top of that, no other company besides us has shown a multiple dose impact on key regulatory cells in patients. Just as we set out to do when this collaboration with Lilly began, the entire development effort, manufacturing included, has been handed off to Lilly at this point. Right now Lilly is running 4 clinical studies of NKTR-358: a placebo-controlled Phase 2 trial in lupus with 280 patients, a placebo-controlled Phase 2 trial in ulcerative colitis with 200 patients, plus 2 separate Phase 1b trials still going, one in psoriasis and one in atopic dermatitis. Over the coming 6 to 18 months, we're expecting data readouts from these studies that Lilly is running. Also, there are plans to bring additional Phase 2 studies into the program before long. Let me pause briefly to welcome our new Chief Medical Officer, Dr. Dimitry Nuyten, who came on board at Nektar last month. Having Dimitri with us during such an exciting period for the company is a real stroke of luck, and he carries with him deep clinical development expertise in immuno-oncology that's going to prove valuable as we move our pipeline forward. During his time at Pfizer, he was the architect and leader of the successful JAVELIN Bladder 100 study, which led to US and European approvals for Avelumab in the first-line maintenance setting for bladder cancer patients. Our clinical strategy and activities will fall under Dimitri's oversight, and that covers direct supervision of clinical sciences, clinical operations, data science and systems, medical affairs and clinical pharmacology. We're eager to see his leadership in action as we carry out our strong development programs for BEMPEG and NKTR-255. With that, I'd like to hand things over to Dmitry. Dmitry?
Dimitry Nuyten
executiveThanks, Howard, for that warm welcome. Let me share a bit about where I come from. I'm a radiation oncologist, and I completed my training at the Netherlands Cancer Institute in Amsterdam. I earned a PhD in cancer biology from the University of Amsterdam. My industry path began at Bristol-Myers Squibb, working in early development in oncology, where I oversaw multiple early development programs. From there I moved to Pfizer, leading clinical development for immuno-oncology, most notably the BAVENCIO, or avelumab, program, which involved several registrational trials, among them RCC and bladder cancer. More recently, I served as Chief Medical Officer at Aduro BioTech. I'm truly thrilled to be joining Nektar, an organization that has pioneered the engineering of cytokine therapies aimed at some of the toughest obstacles in treating cancer and autoimmune disease. Although the potential benefits of therapies built on IL-2 and IL-15 are well understood, the difficulties in making these treatments broadly accessible have slowed the development of agents targeting this pathway. What stood out to me was Nektar's depth of expertise in immune sciences as well as pulmonary chemistry, and together these strengths have produced one of today's most remarkable pipelines in oncology and immunology, with multiple late-stage programs for BEMPEG approaching completion and the clinical development strategy for NKTR-255 now taking shape. I'm eager to collaborate with the remaining program teams and the executive team to advance these programs, with the aim, naturally, of bettering patients' lives. I'll give a brief update on the BEMPEG program and the schedule for registrational studies, which continue to be solidly on track and in line with what we previously communicated. Starting with the 760-patient Phase 3 study in first-line metastatic melanoma, which our partner BMS is conducting. Both we and BMS eagerly anticipate the study's completion and the data to come. BMS brings an outstanding record in melanoma, and nivo holds a very strong and leading market share. That creates a distinctive opening for the BEMPEG plus nivo doublet to potentially serve patients who still lack sufficient treatment choices. As you're aware, BMS is the one running this study, and following the COVID-related enrollment pause, recruitment proceeded very well during the early part of 2021. BMS recently let us know they plan to carry out their initial analysis of the data covering both ORR and PFS endpoints for this Phase 3 melanoma trial once the event count specified in the statistical protocol for the PFS endpoints has been reached. As you know, the PFS endpoint was designed from the start to serve as the endpoint for filing for a full study. BMS and Nektar hold the view that, given the breakthrough therapy designation and a single data analysis at the PFS time point, this strategy will let our teams prepare so that Experis can pursue future regulatory filings once top-line results come in, provided the data supports it. According to what BMS is currently forecasting, the analysis of this data might take place during the first few months of 2022. Because progression-free survival is an event-driven analysis influenced by several variables, the actual pace at which PFS events occur could shift that timeline. Nektar is conducting the subsequent trial — a Phase 3 first-line renal cell carcinoma study of 620 patients that pits BEMPEG plus nivo against either a PKI agent or the physician's choice, which may be sunitinib or cabozantinib. We anticipate possibly hitting our initial interim analysis for the primary overall survival endpoint at some point during the first or second quarter of 2022. In this specific tumor type, BMS and Nektar are pursuing a comprehensive development strategy for BEMPEG plus nivolumab; additionally, BMS is running a 250 patient Phase 2 RCC trial that pairs BEMPEG plus nivo with Exelixis Carbomedics, enabling a comparison of this regimen against the nivo carbo regimen and clearing a path toward a TKI inclusive RCC regimen of BEMPEG plus nivolumab. During the quarter just passed — the first — BMS and Nektar broadened their RCC strategy through a fresh collaboration with Exelixis, which will run a trial assessing BEMPEG plus nivolumab alongside the novel next-generation TKI-XO92. That trial will additionally cover <<inaudible>> cancers, cancer included; as for the Phase 2 first-line CIS-ineligible urothelial carcinoma study, which Nektar is likewise conducting, it is intended to serve as the foundation for a possible accelerated approval filing. Roughly 110 cisplatin-ineligible urothelial carcinoma patients whose baseline CPS score is 10 or lower, used as a measure of PD-L1 expression, are included in this study. The primary endpoint of — pardon me, the primary endpoints consist of overall response rate and duration of response, both determined through central radiology review. In this trial, we aim to reach a median follow-up of 18 months for measuring duration of response, and we likewise anticipate our initial data from this study during the first or second quarter of 2022. The BEMPEG-nivolumab program further includes a sizable Phase 3 trial in muscle invasive bladder cancer and adjuvant melanoma. To begin, our Phase 3 peri-adjuvant muscle invasive bladder cancer study, conducted by BMS, is enrolling about 540 patients, who will first receive BEMPEG plus nivo or nivo monotherapy in a neoadjuvant setting before radical cystectomy, then in the adjuvant setting for a 12-month treatment period after surgery. Given that this study's treatment period is lengthy, we anticipate the initial data readout in 2024; this trial also serves as a confirmatory study for our planned potential accelerated approval in the metastatic intelligible here carcinoma setting. Next, the Phase 3 melanoma trial, which Nektar is running and which is enrolling a total of roughly 950 patients with a 12-month treatment period to surgery and an endpoint of recurrence-free survival by blinded independent central review. Enrollment in this study is currently proceeding rapidly, ahead of schedule. This trial is built to make BEMPEG a standard-of-care option for treating melanoma, and it leans on the rationale behind nivolumab's clearance in that indication. Should it pan out, this trial might substantially grow the pool of melanoma sufferers who could gain from BEMPEG alongside other agents. We anticipate the first set of results from this trial during 2024. Now let me shift to PROPEL, which assesses BEMPEG combined with pembro in non-small cell lung cancer. Per Howard's remarks, we will disclose the first findings from the PROPEL non-small cell lung cancer trial prior to the close of 2021. Like we've mentioned previously, we want a maturity level of no fewer than two scans for those receiving treatment, which lets us grasp the full picture of the doublet's possible clinical advantage as time goes on. To reiterate, our aim is to obtain results from roughly 60 patients, distributed among three distinct PD-L1 expression subgroups, and the trial's design aims to demonstrate the doublet's advantage relative to historical ORRs seen with pembrolizumab as a single agent within the efficacy evaluable population treated in the under 1%, 1% to 49%, and at least 50% PD-L1 expression subgroups.
Dimitry Nuyten
executiveIn non-small cell lung cancer, there's a well-recognized link between the level of inflammation present in the tumor microenvironment and how effective a single-agent checkpoint inhibitor such as pembrolizumab turns out to be. What governs this is PD-L1 expression status. Patients falling into the greater than 50% subgroup, as we've noted previously, derive the greatest benefit from pembrolizumab used alone, and that's tied to the mechanism of BEMPEG — it aims at and amplifies the inflammatory condition of the tumor of regulation, PD-L1 in the tumor microenvironment. Accordingly, we believe that combining BEMPEG with pembro in non-small cell lung cancer could enhance the doublet's effectiveness across several PD-L1 expression subgroups. We recently introduced a chemo combo cohort into PROPEL, which gives us a chance to possibly add the doublet to chemo choices within our Phase 2 approach. This effort, together with the early PROPEL results, will allow us to determine a full Phase 3 plan for BEMPEG in non-small cell lung cancer. Regarding the new registrational Phase 2/3 head and neck cancer trial, as Howard mentioned, we're running ahead of timeline and expect to start enrolling our first patients in the coming months. For this study, we have partnerships set up with Merck and SFJ Pharmaceuticals, and we're quite enthusiastic about the opportunity to serve a sizable patient group in the frontline setting. This trial involving more than 500 participants is designed to enable a possible worldwide filing for the BEMPEG and pembro combination. An interim look at ORR is planned once the initial 200 subjects have been enrolled. Should that ORR clear a futility threshold set in advance, the trial moves forward, with the next 300 subjects joining the Phase 3 segment, bringing the total to 500 who can be assessed for the primary goals of ORR and overall survival. With the competitive picture looking favorable, we regard this as a rare chance to position BEMPEG as the first therapy based on the IL-2 mechanism in head and neck cancer. I'll now hand things over to JC, who's going to walk us through the NKTR-255 program as well as the Lily NKTR-358 program.
Jonathan Zalevsky
executiveThanks, Dmitry. I'll begin by discussing NKTR-255, an agent that taps the complete IL-15 pathway biology, delivering functional activation along with homeostatic regulation of the IL-15 response in immune cells — specifically natural killer cells, CD8 T cells, and immune memory subsets. Because it acts as a full-pathway IL-15 agonist, NKTR-255 is positioned to pair with a range of mechanisms, from targeted agents to cell therapy and even immunological checkpoints, with the aim of potentially boosting how well those work. Back in May, we came out with our first peer-reviewed manuscript covering NKTR-255, which appeared in the Journal of Immunotherapy of Cancer, or JITC. That paper lays out a head-to-head assessment of NKTR-255 against a pre-complex IL-15 agonist, which makes up the bulk of the competitive IL-15 pipeline. NKTR-255 showed meaningful differentiation relative to the pre-complex IL-15 agonist, in that NKTR-255 engages the entire spectrum of IL-15 biology while also having an extended pharmacokinetic and pharmacodynamic profile. Taken together, these characteristics of NKTR-255 drove increases in functionally competent cytotoxic NK cells within the tumor microenvironment, and on the whole this converted into higher survival rates and better antitumor activity in the B-cell lymphoma model compared with those pre-complex cytokines. And, as Howard noted, we're initially concentrating on antibodies that work via an ADCC mechanism of action. We've put together a clinical strategy to combine with top targeted antibodies across both liquid and solid tumor settings; for our Phase 1/2 study in patients with relapsed refractory malignancy, we anticipate finishing the monotherapy dose escalation portion of the trial later this year, and we intend to share the data from those monotherapy dose escalation cohorts at a medical meeting later this year. As the trial moves forward, we'll broaden into several arms of roughly 20 patients each. One arm will assess NKTR-255 as monotherapy or combined with rituximab in third-line or greater follicular lymphoma or low-grade NHL. In another arm, we'll assess NKTR-255 as a monotherapy and combined with DARZALEX FASPRO in third-line or greater multiple myeloma. A third arm will assess NKTR-255 as a monotherapy for NHL patients who have already progressed after approved CD19 CAR T cell therapy. Our second clinical study is assessing NKTR-255 combined with cetuximab in two separate groups of highly refractory late-line patients who have metastatic colorectal cancer or head and neck cancer. We're enrolling up to 80 patients across the US and Europe. As you're aware, cetuximab has a very low response rate, roughly 10% or 15% in the extent. And our aim is to improve on that by adding NKTR-255, which would then offer several potential paths forward for the program. Now this study starts with a dose escalation run where we assess cetuximab combined with rising dose levels of NKTR-255. We've already finished the first dose escalation cohort at the lowest dose and have fully enrolled the second dose cohort. Once we finish dosing with an additional cohort for the combo, the trial will grow to include focused groups of colorectal cancer and head and neck cancer patients. Later in the year, at a medical conference, we intend to share some preliminary findings from the dose-escalation cohort for that part of the trial. Now let's move over to immunology. Like Howard mentioned before, we're quite happy about how wide-ranging the development effort is and how far the NKTR-358 program has come under our collaborator, Eli Lilly. A number of autoimmune and inflammatory conditions, such as systemic lupus and ulcerative colitis, come with lower Treg counts, impaired Treg activity, and/or diminished IL-2 production. Through NKTR-358, we aim to tackle these Treg irregularities and create a molecule resembling IL-2 that might target Tregs selectively and more effectively than low-dose IL-2 does. Back in May of this year, we also reported that our preclinical findings had been published in the Journal of Translational Autoimmunity. That paper lays out the core science underlying NKTR-358 and the promise it holds for treating a wide spectrum of autoimmune conditions. And truly, we've watched that preclinical evidence carry over into encouraging clinical results, with favorable outcomes in lupus patients shared at both UR and ACR last year. After those results, Lily kicked off the Phase 2 lupus trial. Subsequently, early this year, Lilly launched a Phase 2 trial for ulcerative colitis. Lilly is likewise pushing ahead with the 2 distinct Phase 1b trials in psoriasis and atopic dermatitis. The lupus Phase 2 trial is moving along quite well. To recap, 280 patients are being assigned at random to 1 of 3 doses of NKTR-358 or to placebo. Dosing happens once every 2 weeks across a 24-week treatment window. The main goal of the Phase 2 trial is the proportion of patients who reach a minimum of a 4-point drop on the SLE disease activity index, or scale. Typical clinical composite endpoints seen in lupus research also appear among the secondary endpoints. We'll further assess pharmacokinetics, pharmacodynamics, and immunogenicity among those receiving treatment. Measurements of endpoints take place at week 24, and we anticipate finishing the trial in 18 to 24 months. Also earlier this year, Lilly started a randomized, placebo-controlled Phase 2 trial in ulcerative colitis patients and started signing up patients during the first quarter of this year. Using an adaptive design, the trial will test several dose levels through the initial induction phase. The plan is to enroll 200 patients in total. The trial's endpoint is the proportion of patients in clinical remission following induction treatment at 12 weeks. Beyond that, as Howard noted before, we understand Lilly intends to keep expanding the NKTR-358 development program, with plans to launch two more Phase 2 trials in two new indications. We're happy with how quickly Lilly has moved the program forward and their interest in developing this agent across a broad range of inflammatory and autoimmune diseases. To wrap up, we're eager about what a potential presentation might show from the ongoing Phase 1b trial in psoriasis and atopic dermatitis involving NKTR-358, with findings from at least 1 of those studies slated for a medical meeting within the coming year. Before passing the call over to Gil, I want to provide an update regarding our COVID-19 study. I'm happy to share that as of today the study has finished, and the results we've gathered are encouraging. As a quick reminder, this was built as a Phase 1b randomized, double-blind, placebo-controlled trial, assessing just a single dose of BEMPEG or placebo administered to 30 adult patients who had confirmed mild COVID-19 infection. You'll remember the scientific hypothesis behind the study was to determine if BEMPEG might raise Absolute Lymphocyte Counts, or ALC, across an eight-day span in mild COVID-19 patients versus placebo. Studies have demonstrated that patients diagnosed with COVID-19 who arrive with a low baseline ALC face a far greater chance of progressing to severe disease and needing hospitalization. Within this trial, we assessed three escalating single doses of BEMPEG: 0.00075 milligrams per kilogram, 0.0015 milligrams per kilogram, and 0.003 milligrams per kilogram. For context, the highest dose examined here equals 50% of the Q3 week dose being used in our registrational studies of BEMPEG plus nivolumab in cancer patients. On the whole, single doses of BEMPEG were well tolerated among mild COVID-19 patients, with AE resembling what our earlier experience with BEMPEG monotherapy in cancer patients would lead us to expect. That was a key finding, since it shows BEMPEG can be given to patients dealing with underlying viral-induced inflammation. The study achieved its primary objective, and we saw a clear dose response in absolute lymphocyte count increase from baseline through day eight across the different BEMPEG dose levels; among the 15 placebo patients measured over that eight-day period, there was an overall reduction in ALC from baseline. Even though this study wasn't built for efficacy and those enrolled had only mild symptoms, we saw a shift on the WHL clinical progression scale for the five patients given the highest BEMPEG dose, with most of them showing symptom improvement by day eight relative to patients who received placebo doses in the study. We're still reviewing these results and intend to share them with our advisers, who are experts in this area; we've also been closely monitoring the COVID situation, the combination of vaccines, the simply evolving COVID-19 variant, and the rising count of long COVID cases. And should there appear to be a lasting need to augment today's therapy, we want to be ready to move forward. We’re eager to keep all of you informed about what comes next on this front after we return to our advisers and get the opportunity to carefully assess the unmet need. And although we’re excited about what BEMPEG could offer in virology, naturally, our top development priority for BEMPEG is oncology treatment. So with that, I’ll hand things over to Gil.
Gil Labrucherie
executiveThanks, JZ, and good afternoon to all of you. During this call, I'll walk through our 2021 financial guidance, and that guidance has not changed for the year. When the second quarter closed, we had more than $1 billion in cash and investments, and our plan is still to finish the year holding at least $750 million in cash and investments, with no debt sitting on the balance sheet. Because of that, our financial position remains very strong. As we get closer to top line results from the three registrational studies for BEMPEG, starting in early 2022, you'll remember that we also have substantial regulatory and approval milestones for BEMPEG through our BMS collaboration. The milestones include $625 million that's contingent on BEMPEG getting approved and launched for its first indication across the US, European Union and Japan, and then $260 million for each of the following three indication approvals for BEMPEG. So we're in a strong position to prepare for BEMPEG's commercial launch, potentially in the second half of 2022, while also continuing to advance our broad portfolio of development programs. Just to remind everyone, we're guiding to roughly $100 million in GAAP revenue for the full year, which breaks down as $15 million to $20 million from product sales and $80 million to $85 million from non-cash royalties. We expect to book the remaining revenue fairly evenly across the back half of the year. For GAAP R&D, our guidance remains in the $450 million to $500 million range. Spending on R&D ought to climb during that second half as enrollment keeps growing across our wide clinical development portfolio. As we mentioned before, site activation is now underway for the BEMPEG head and neck trial, and patients should start enrolling before the year is out. Enrollment is also continuing at a substantial pace in the Phase 3 adjuvant trial for BEMPEG and in the NKTR-255 program. Meanwhile, Eli Lilly, our partner, is still adding patients and broadening the NKTR-358 development effort. Looking at our guidance for R&D expenses, it contains roughly $85 million in non-cash items, which come from stock compensation, non-cash depreciation, and SFJ's funding of the head and neck cancer study. For G&A, we still expect a range of $120 million to $125 million, and that figure includes about $35 million in non-cash depreciation and stock compensation. Non-cash interest expense should land somewhere between $50 million and $60 million, driven by monetizing our royalty streams. On top of that, non-operating expense carries roughly $15 million tied to accounting for the contingent success-based payments to SFJ as a derivative liability. With all of that said, I'd like to turn the call over to questions. Operator?
Analyst
analystGood evening. CJ here, filling in for Chris tonight. I'd like to know what's holding things up in terms of timing for when the PROPEL data will come out later this year. Is it that enrollment has wrapped up? Or is the only thing left the follow-up? Also, I'm wondering whether the readout will include any data from the chemo cohort too. Thanks.
Jennifer Ruddock
executiveAppreciate that, CJ. JZ, could you handle this question for us? Thanks so much.
Jonathan Zalevsky
executiveAbsolutely, and thanks for raising that, CJ. As we mentioned before, things are moving along nicely when it comes to accrual in the PROPEL trial. On prior calls, we shared guidance that toward the very end of last year, we observed a fairly substantial uptick in patients joining, especially once COVID began to subside across Europe, where the majority of sites for that trial are located. Given the group of patients we've enrolled, our aim was to make sure they'd yield the fullest, most mature, and most robust dataset possible; that's the reason we're aiming at the latter half of this year to present those results. One thing you can anticipate from that presentation is that we'll share every piece of information we've gathered on the patients we've been tracking within those groups. There are three distinct subgroups in this trial, split according to PD-L1 expression levels. Those fall into the under 1% PD-L1 group, the 1% to 49% group, and the over 50% group. Our plan is to deliver the complete spectrum of findings. That means everything from safety readout correlations, to all efficacy details such as ORR, CR, the composite endpoint, and any time-to-event data that has built up as well. We're eager to present all of that before this year is out. Turning to the latter portion of your question: the cohorts that include chemo, which represent the most recent additions to the trial, are currently open and recruiting patients; however, it's probably premature to share any results from them, since those groups have only just begun enrolling people.
Jay Olson
analystHey there, appreciate you taking my question. Perhaps I could pose something broader in scope. Given that your BEMPEG trials pair it with nivo and pembro, should we think there's some basis for expecting BEMPEG to produce stronger synergies alongside PD-1 antibodies rather than PD-L1 antibodies? Alternatively, would you anticipate those pairings to offer the same level of synergy? Thanks so much.
Jennifer Ruddock
executiveJZ, I'll hand that one over to you right now. Thanks.
Jonathan Zalevsky
executiveAbsolutely, and thanks for asking that, Jay. So, regarding that mechanism—clearly, the receptor here is PD-1 while the ligand is PD-L1. And I believe you're also aware there exists a second line, PD-L2, which can bind to the PD-1 receptor too. So you have several ligands interacting with one receptor. From what we've observed throughout the various pipelines—for instance, looking at how drugs such as durva from AstraZeneca perform, or Atezo from Genentech and Roche, or avelumab, which is BAVENCIO from EMD along with Pfizer—you notice these molecules showing efficacy across a variety of tumor types. That much is certain. However, what we've also noticed is that Merck's pembro, or KEYTRUDA, has genuinely captured an extremely dominant portion. And it has secured approval for, really, the largest number of distinct tumor types. So there are unquestionably far more possibilities where Merck's pembro serves as the first-line standard of care, whether that's in a monotherapy or a combination setting. A crucial component of our approach involves pairing BEMPEG with a checkpoint inhibitor. As you can tell from our development plan, we are truly giving priority to indications where the single-agent checkpoint is the standard of care and, ideally, in the first line. That naturally generates additional opportunities within the PD-1 subclass as well as the PD-L1. But if you were to ask me purely as a scientific matter, I can genuinely envision the scenario in which the mechanism of adding BEMPEG would deliver considerable synergy to either a PD-1 or a PD-L1 inhibitor.
Jessica Fye
analystHi everyone, good afternoon, and thanks for the opportunity to ask. So regarding the PROPEL data, one angle is that to understand what BEMPEG is contributing, comparing those combo results against what you'd anticipate from single-agent pembro seems worthwhile. Yet from a practical perspective, the competitive benchmark, clinically speaking, would appear to be the KEYNOTE-189 data. So given that, do you in fact have a path you're keen to pursue for this doublet combination? Or does this represent a step on the way toward eventually moving the triplet forward?
Jennifer Ruddock
executiveJZ, would you like to take that one? Thanks.
Jonathan Zalevsky
executiveAbsolutely. Jess, thanks for bringing that up. I believe your question does a great job of capturing the situation. We're aware that using pembro alone or sparing chemo is clearly the leading approach among patients whose PD-L1 is above 50%; that applies to the global label, correct? So in that group, KEYTRUDA is administered as a single agent nearly everywhere it has received approval. However, among those whose expression falls below 50% — say 1 to 49, or under 1 — the picture varies considerably. When expression is under 1, it is invariably given alongside chemo. Within the 1 to 49 group, health authorities differ somewhat. Here in the US, pembro carries approval for the 1 to 49 population, yet that isn't true beyond the US, where it gets used together with chemo. Consequently, multiple avenues exist for influencing how treatment is approached; take, for instance, the substantial chance to boost pembro's overall activity. As Howard mentioned during his earlier presentation, our effects still top out at roughly 2 times. That leaves plenty of room, particularly with BEMPEG, to prolong that maintenance phase and deliver stronger durability of response. Another avenue involves building a chemo-sparing choice. A number of patients cannot receive chemo, so we can serve that group; beyond that, there's always room to give physicians yet another treatment possibility to weigh, whether combined with chemo or not. Furthermore, looking at our long-range plans with PROPEL, we've now launched cohorts that incorporate chemo combinations. This lets us target BEMPEG plus pembro alongside chemo, with varying chemos selected according to the disease's distinct histologies. Through that sort of approach — BEMPEG plus pembro, or BEMPEG plus pembro and chemo — we can reach every distinct population and essentially the whole treatment landscape in non-small cell lung cancer. We're eager to share some of those findings later in the year, and as the chemo-containing cohorts keep enrolling, more will follow down the road. Thanks for asking.
Analyst
analystHello there, good afternoon. Alex here, filling in for Difei. I appreciate you taking my question. I wanted to revisit the lung cancer data. And — would it be reasonable to say that you could begin the registrational trial of the combo sometime next year, once you've reviewed the initial data; and afterward you'd do something involving the chemo? Thank you.
Jennifer Ruddock
executiveJZ, would you like to discuss what our thinking is regarding the Phase 3 strategy? Thanks.
Jonathan Zalevsky
executiveYes, absolutely. The way the PROPEL trial is built, you see, is really meant to generate a strategy that can guide Phase 3. That's the reason these initial cohorts look at BEMPEG combined with pembro, and they look at patients split up according to PD-L1 expression subgroups. Like I said before, that runs from below 1% to 1 to 49 and above 50. So the whole point is to pinpoint the places showing the strongest signal, and those findings shape various possible Phase 3 designs; take, for instance, a chemo-sparing scenario — you might think about a Phase 3 trial comparing pembro alone against the combination of bempeg plus pembro, say, within the above 1% PD-L1 expression group. So that's one option that might come out of this. Of course, the plan when we report data later this year is to have Nektar in a spot where it can advance into Phase 3 should the data support that; and then, getting right to what you asked, the extra chemo cohorts we've put into PROPEL provide that further chance to investigate yet more treatment regimens involving BEMPEG plus pembro; and in that case, we'd be looking at a different type of comparator within a registrational context; for instance, we'd be studying pembro plus chemo against BEMPEG plus pembro plus chemo while aiming at a different patient population, with the focus now much more on those below 1%.
Analyst
analystHi there. <<inaudible>> here, filling in for Alex Ramsey. Thanks for taking my question. We've come across some research indicating that NSAIDs, when given prophylactically in that context, might weaken the humoral immune response. So we were hoping you could remind us what the BEMPEG trials' protocol says regarding NSAID dosing? And in particular, NSAIDs taken with BEMPEG to help with symptoms?
Jennifer Ruddock
executiveSure. Thank you, Alex. JZ, could you walk us through the protocol specifics? Thanks.
Jonathan Zalevsky
executiveAbsolutely, and hey Alex, I appreciate you asking that. To start off, I want to make it clear that this wasn't a study focused on a vaccine. The patients we enrolled had mild cases of COVID-19, and they had already been confirmed positive through a COVID PCR test. So in that sense, it falls under the vaccine study category; and then regarding your broader question about NSAs, whether they can be utilized or if they ever are, we do give doctors the chance to apply standard of care. So when it comes to patients who may have experienced some undesirable inflammation, if a physician believed it was necessary to administer an NSAID, or something over-the-counter, or Tylenol, for instance, those would be options since they represent typical standard of care for managing COVID in general. I hope that answers your question.
Analyst
analystYes. Good afternoon, everyone. Neil Carnahan here, filling in for Ben. Regarding the PROPEL study, I was curious: could there be a situation in which one PDL expression group appears more favorable compared to the rest, no matter which combination arm is involved, and that you would use that to enrich for such a patient group in the pivotal study?
Jennifer Ruddock
executiveJZ, would you like to take that one?
Jonathan Zalevsky
executiveYeah. I'm not certain I grasp what you're asking. So perhaps I'll respond to what I believe your question was. The manner in which that trial was carried out is that when patients came in, we basically signed them up and afterward took biopsies, and central testing was used to assess their PD-1 — PD-L1 levels; after that they get placed into various subgroups based on what their status is. And therefore every patient receives the doublet BEMPEG plus pembro; so we will be assessing each of the separate subgroups. Each of them will be assessed simultaneously. Perhaps what you also meant is that when we examine the data down the road, we might observe a stronger signal in one subgroup, say, compared with another. So for instance, here are a few benchmarks; we know that single agent pembro has roughly an 8% response rate among the less than 1% population and roughly a 15% to 17% response rate among the 1% to 49% population; so those are two areas in which single agent pembro has far less activity, much, much less than it has shown in the greater than 50% population. So it's entirely reasonable given how BEMPEG works that we might observe stronger activity in those subgroups with lower PD-L1 expression; and should that be what the data shows, then that's the sort of thing that would shape our Phase 3 strategy moving forward if the data supports it. I hope that addresses your question, since I'm not sure I completely grasped it.
Analyst
analystThat answers it, thanks. The follow-up I had was the thing I was attempting to ask about. Thanks for that.
Jonathan Zalevsky
executiveAll right. Of course.
Daina Graybosch
analystHello, and thank you for taking my question. I'd like to ask about the melanoma trial's interim analysis. From what I gathered, assuming I understood you correctly, the interim evaluation will now look at our results jointly — did the interim design get modified? Or might we be witnessing a COVID-related effect, much like what BMS observed in their rolatamab trial, in which the interim lagged behind PFS and we simply haven't seen it happen yet — is that the issue? Additionally, could you verify the current status of NKTR-26 2 — is that program still running?
Jennifer Ruddock
executiveThank you, Dana. JZ, would you like to address those two questions? Thanks.
Jonathan Zalevsky
executiveAbsolutely. Thanks, Dana, for those questions. So regarding the first data analysis, one thing we did is that once the study started — right, since it began in 2018 — as you'll recall, in 2019 Nektar, together with BEMPEG, received Breakthrough Therapy Designation in first-line melanoma. That was based on how strong the PIVOT-02 data were in first-line melanoma, where BEMPEG placebo demonstrated a very high complete response rate of 34%, and we also recently presented a progression-free survival that was very, very long, at almost 31 months. So with Breakthrough Therapy Designation, that provides a great deal of real firepower when it comes to the potential from the regulatory review in the filing. And so BMS and Nektar jointly reached a decision that we would run the analysis of both the ORR endpoint and the PFS endpoint as soon as the trigger for the PFS events — which is predefined in the protocol's statistical analysis plan — is reached. And so this is a very, very powerful thing, because now we'll be able to present both sets of data and use the Breakthrough Therapy Designation as an opportunity to submit that for a full approval for BEMPEG plus nivo in first-line melanoma. And so that's a very good one that we made together with BMS, yes. And as Howard stated earlier, the first half of 2022 is when we expect that study's results to read out. Dana, for the second part of your question, you asked about the NKTR-262 program, and that program remains active; in fact, we look forward to presenting results from the ongoing REVEAL trial in the future. One of the things we've been studying in the REVEAL trial are a couple of additional cohorts of 262. One is 262 plus BEMPEG and the other is 262 plus BEMPEG plus nivo; and those two cohorts that we evaluated have completed enrollment. We're assessing the data, and we'll look forward to presenting that at a medical meeting in the future.
Arlinda Lee
analystHey, everyone. Appreciate you fielding these. I've got one more about PROPEL — apologies for bringing it up again. Could you make it clear that for the data coming later in the year, there won't be a great deal of chemo data? Then, Gil, would you remind us what sort of financial arrangements exist with Merck that could assist with the upcoming steps? And third, regarding the 255 data flow, you said the heme monotherapy dose escalations have finished; so are we going to see any combination data? And then — that's all. Thanks so much.
Jennifer Ruddock
executiveJZ, would you like to give those a try. Thank you.
Jonathan Zalevsky
executiveSure, I can take that one.
Jennifer Ruddock
executiveOne of those you already addressed before, though JZ is able to say it again.
Jonathan Zalevsky
executiveAbsolutely. I'll take the first and the third, and then hand things over to Gil for the one in the middle, which is about the financials. So when it comes to PROPEL, enrollment in the chemo cohorts has only just begun. That means we won't have data from those groups to show later this year. Again, it's simply that they are at a very, very early stage of enrolling patients. And as you can tell from our clinical trials post and similar materials, those cohorts opened only a short time ago. So those results will arrive down the road, Arlinda. Then regarding 255, dose escalation in monotherapy is still ongoing. Our belief is that we will complete that dose escalation later this year. And what we intend to present at a medical meeting later this year is the full set of results gathered from the 255 program so far. Those will center on monotherapy dosing of 255, and we will include everything we've collected regarding NK — the pharmacokinetics, all of the pharmacodynamics for NK cell expansion, CD8 T cell expansion, the impact on the memory pool, and also our continued evaluation of patients in the post-CAR-T setting, where we have already reported activity, showing rises in CAR T cells months following CAR-T administration. So that gives you a sense of what to expect from 255. And Gil, over to you for the financial question about Merck.
Gil Labrucherie
executiveAbsolutely. Thank you, JZ. Hey, Arlinda. As you know, the collaboration we made public in February alongside SFJ and Merck played a major role in our Phase 2.3 head and neck trial, since both offered guidance on regulatory matters and study design that helped shape the trial's final format. And what's more important, they're putting in roughly $60 million worth of pembro for the study. For us, that represented a significant component of the entire transaction, somewhere between 25% and 30% of all study expenses. So they truly were an essential element of that partnership. Regarding future plans, clearly, as we've mentioned during this call, we'll keep assessing Phase 3 approaches together with BEMPEG, and we'll find out what options emerge as those take shape.
Howard Robin
executiveOkay, so thanks to each of you for being here with us right now. We're definitely moving into a period that's both busy and exciting for Nektar, with several important data readouts beginning later in the fall, and all of us are very much looking forward to seeing melanoma data early next year. I want to express appreciation to our employees and to our efforts and for helping us get to these milestones through these difficult times, and I also want to thank our shareholders for sticking with us. We're eager to bring you updates about how we're progressing. Keep watching. Thanks.
Operator
operatorAppreciate it; that wraps up the conference call for today. Thanks for joining us, and at this point you're free to disconnect. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.